A gene recombinant influenza vaccine is expected to be released in Korea. Currently, flu vaccines made by using eggs or culturing cells are also on sale in Korea. The MFDS approved a phase 3 clinical trial plan for Sanofi's RIV4 vaccine on the 2nd. RIV4 is an abbreviation for Quardrivalent Recombinant Influenza Vaccine, which, in direct translation, is a quaternary recombinant influenza vaccine.

This test is aimed at describing the immunogenicity and safety of quaternary recombinant influenza vaccines compared to quaternary inactivated influenza vaccines in 300 patients aged 18 or older in Korea. A tetravalent recombinant influenza vaccine has not yet been released in Korea. The recombinant influenza va